![]() ![]() Liang brings nearly three decades of combined experience in management, financing, strategy, and research in the biotechnology and pharmaceutical industries and investment research on Wall Street. Howard Liang joined Tessera in 2021 as President and Chief Financial Officer. Howard Liang, Ph.D., President and Chief Financial Officer I am excited to be working with him, and our other new senior leaders, each of whom will be instrumental in expanding the limits of how we discover life-changing medicines.” “Howard’s track record in both strategy and finance at BeiGene and in the capital markets will play a key role in guiding Tessera to new territory in Gene Writing. Geoffrey von Maltzahn, CEO and Co-Founder of Tessera and General Partner, Flagship Pioneering. “Outstanding people are the lifeblood of great companies and I’m thrilled to welcome these accomplished individuals to the Tessera leadership team,” said Dr. Tessera also announced the successful completion of $230 million Series B financing in January. These additions represent the latest leadership expansion for the company, following the appointments of Elliott Sigal, M.D., Ph.D., and Mary Rozenman, Ph.D., to the Board of Directors in June, and the appointments of David Davidson, M.D., as Chief Medical and Development Officer, Hari Pujar, Ph.D., as Chief Operating Officer, and Lin Guey, Ph.D., as Senior Vice President of Rare Diseases Program Strategy and Operations in March. as Senior Vice President, Platform Development Vikram Ranade, Ph.D., as Senior Vice President, Corporate Development David Pollard, Ph.D., as Head of Bioprocess, and Steve Garbacz as Head of Finance. The company also expanded its executive bench with newly promoted talent and hires: Madhusudan Peshwa, Ph.D., as Chief Technology Officer for Cell Therapy Bill Querbes, Ph.D., as Senior Vice President, Therapeutic Discovery & Translational Sciences Cecilia Cotta-Ramusino, Ph.D. CAMBRIDGE, Mass.-( BUSINESS WIRE)-Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, announced today the appointment of Howard Liang, Ph.D., as President and Chief Financial Officer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |